-
Mashup Score: 0
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally tolerated it well, according to data published in The Lancet Respiratory Medicine.“Vanzacaftor-tezacaftor-deutivacaftor was safe and well tolerated and maintained FEV1 percent predicted from elexacaftor/tezacaftor/ivacaftor baseline with further improved CFTR
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 0
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally tolerated it well, according to data published in The Lancet Respiratory Medicine.“Vanzacaftor-tezacaftor-deutivacaftor was safe and well tolerated and maintained FEV1 percent predicted from elexacaftor/tezacaftor/ivacaftor baseline with further improved CFTR
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
Published in @LancetRespirMed📣: Patients aged 6 to 11 years with #CysticFibrosis receiving 24-week once-daily #vanzacaftor/#tezacaftor/#deutivacaftor generally tolerated it well. #Alyftrek @VertexPharma Read more⬇️ https://t.co/KWMBiwjNwB